Analyst Price Targets — CLMT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 13, 2026 2:27 pm | Manav Gupta | UBS | $26.00 | $28.51 | TheFly | Calumet price target raised to $26 from $13.25 at UBS |
| January 30, 2026 12:19 pm | Neil Mehta | Goldman Sachs | $24.00 | $22.39 | TheFly | Calumet price target raised to $24 from $20 at Goldman Sachs |
| October 22, 2025 10:23 am | — | Goldman Sachs | $20.00 | $18.67 | TheFly | Calumet price target raised to $20 from $15 at Goldman Sachs |
| August 12, 2025 11:32 am | Manav Gupta | UBS | $13.25 | $13.88 | TheFly | Calumet price target raised to $13.25 from $12 at UBS |
| March 5, 2025 12:25 pm | — | Wells Fargo | $28.00 | $12.98 | TheFly | Calumet price target lowered to $28 from $29 at Wells Fargo |
| December 14, 2022 9:16 am | — | UBS | $15.70 | $13.48 | Benzinga | UBS Initiates Coverage On Calumet Specialty with Neutral Rating, Announces Price Target of $15.7 |
| April 21, 2022 7:25 am | — | Wells Fargo | $29.00 | $14.27 | Benzinga | Wells Fargo Maintains Overweight on Calumet Specialty, Raises Price Target to $29 |
Latest News for CLMT
INDIANAPOLIS, March 4, 2026 /PRNewswire/ -- TRUFUEL®, an industry leader in precision-engineered fuel, has achieved the highest monthly sales volume in the company's history, eclipsing the brands' previous monthly high by over 10%. This milestone, which comes on the heels of a record sales year in 2025, reflects the growing reliance on TRUFUEL by customers who depend on their equipment to perform when it matters…
Calumet (NASDAQ: CLMT) executives used the company's fourth-quarter and full-year fiscal 2025 earnings call to highlight what CEO Todd Borgmann described as a "defining high impact year," pointing to improved profitability, lower leverage, and the closing of a U.S. Department of Energy (DOE) loan at Montana Renewables as key strategic achievements. Management said 2025 milestones included
It boosted revenue nicely in its fourth quarter. Yet it still posted a net loss for the period.
Calumet, Inc. (CLMT) Q4 2025 Earnings Call Transcript
Fiscal Year 2025 net loss of $33.8 million, or basic loss per common share of $0.39 Fiscal Year 2025 Adjusted EBITDA with Tax Attributes of $293.3 million $222 million of recourse debt reduction in 2025 Strong free cash flow driven by approximately $100 million of cost reduction initiatives in 2025 Record production year in Specialty Products & Solutions segment and Montana Renewables Montana Renewables MaxSAF®150…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLMT.
U.S. House Trading
No House trades found for CLMT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.